Fishman Jay A Ltd. MI Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fishman Jay A Ltd. MI reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 32.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,810 shares of the company's stock after selling 9,034 shares during the period. Fishman Jay A Ltd. MI's holdings in Johnson & Johnson were worth $3,119,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Tallon Kerry Patrick purchased a new stake in Johnson & Johnson during the fourth quarter valued at $290,000. Capital & Planning LLC raised its position in shares of Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after buying an additional 183 shares in the last quarter. Brighton Jones LLC grew its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Johnson & Johnson during the fourth quarter worth approximately $85,886,000. Finally, Cannon Financial Strategists Inc. raised its position in Johnson & Johnson by 7.1% during the fourth quarter. Cannon Financial Strategists Inc. now owns 2,701 shares of the company's stock valued at $391,000 after purchasing an additional 178 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.6%

Shares of Johnson & Johnson stock traded up $0.95 during trading on Tuesday, hitting $152.27. 9,539,679 shares of the stock traded hands, compared to its average volume of 8,001,956. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock's fifty day simple moving average is $154.01 and its 200 day simple moving average is $153.69. The firm has a market cap of $366.36 billion, a P/E ratio of 16.94, a price-to-earnings-growth ratio of 2.29 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.42%. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JNJ. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Barclays lowered their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Bank of America reduced their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.